How many drug targets are there?
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
For the past decade, the number of molecular targets for approved drugs has been debated. Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus number of current drug targets for all classes of approved therapeutic drugs. One striking feature is the relatively constant historical rate of target innovation (the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower. The recent approval of drugs that target protein kinases highlights two additional trends: an emerging realization of the importance of polypharmacology, and also the power of a gene-family-led approach in generating novel and important therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, G-protein-coupled receptors (GPCRs) are influenced by trafficking progress and then internalized in the cell membrane and recycled or degraded.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
In the citing paper
“Covalent molecules may not be able to effectively target GPCRs during this turnover process [127].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The Pfam Protein Families Database
Bateman, A. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.276 · Cited by 14,000
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Murzin, A. G., Brenner, S. E., Hubbard, T., & Chothia, C. (1995) · Journal of Molecular Biology · doi:10.1016/s0022-2836(05)80134-2 · Cited by 7,012 · cited 1×
“Patterns in drug targets In order to identify the familial relationships between all drug targets, we analysed the presence of domains, using the SCO”
MethodDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“drugs acted primarily through only 120 underlying molecular target”
BackgroundSelf-citationThe Pfam protein families database
Bateman, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh121 · Cited by 3,127
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“Imatinib, originally developed as a highly selective inhibitor of c-AB”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“(and which target association led to its first approval for chronic myeloid leukaemia), has subsequently been discovered to be have significant activity against several other clinically relevant kinases, such as c-KI”
Background
Research works printed but not linked: 1
- Christensen, C. M. The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (Harvard Business School Press, Cambridge, 1997).
Cited by
Items 1,001–1,024 of 1,024
Sherbiny, F. F., Schiedel, A. C., Maaß, A., & Müller, C. E. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9299-7 · Cited by 45
“GPCRs are single polypeptide chains having seven hydrophobic transmembrane-spanning segments (7TM) that couple to an effector molecule through a trimeric G protein complex [3].”
BackgroundInfluentialSipe, S. N., Patrick, J. W., Laganowsky, A., & Brodbelt, J. S. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.9b03689 · Cited by 39
Ebenezer, O., Comoglio, P., Wong, G. K.-S., & Tuszynski, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044019 · Cited by 39
HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes
Xiao, T., Frey, G., Fu, Q., Lavine, C. L., Scott, D. A., Seaman, M. S., Chou, J. J., & Chen, B. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0496-y · Cited by 38
Wu, X., Wang, L., Han, Y., Regan, N., Li, P.-K., Villalona, M. A., Hu, X., Briesewitz, R., & Pei, D. (2011) · ACS Combinatorial Science · doi:10.1021/co200057n · Cited by 36
Langelaan, D. N., & Rainey, J. K. (2010) · Biochemistry and Cell Biology · doi:10.1139/o09-129 · Cited by 35
“For example, G-protein coupled receptors (GPCRs) are the therapeutic target of ~1/4 of all top-selling prescription drugs, even though only ~10% of GPCRs are drug targets (Overington et al. 2006).”
BackgroundBartholow, T. G., Burroughs, P. W. W., Elledge, S. K., Byrnes, J. R., Kirkemo, L. L., Garda, V., Leung, K. K., & Wells, J. A. (2024) · ACS Central Science · doi:10.1021/acscentsci.3c01473 · Cited by 32
TRPMLs and TPCs: targets for lysosomal storage and neurodegenerative disease therapy?
Krogsaeter, E., Rosato, A. S., & Grimm, C. (2022) · Cell Calcium · doi:10.1016/j.ceca.2022.102553 · Cited by 31
Recent advances in automated protein design and its future challenges
Setiawan, D., Brender, J., & Zhang, Y. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1465922 · Cited by 26
“Because of their central role in cell signaling and regulation, they are highly overrepresented in both current drug targets and in estimates of future ones [18].”
BackgroundXie, L., & Xie, L. (2023) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1010974 · Cited by 26
“It is estimated that only 2–5% of the human genome is druggable by small molecule drugs [1, 2].”
Kathwate, G. H., Shinde, R. B., & Karuppayil, S. M. (2015) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2015.29007.ghkdrrr · Cited by 25
The chemical interactome space between the human host and the genetically defined gut metabotypes
Jacobsen, U. P., Nielsen, H. B., Hildebrand, F., Raes, J., Sicheritz-Ponten, T., Kouskoumvekaki, I., & Panagiotou, G. (2013) · The ISME Journal · doi:10.1038/ismej.2012.141 · Cited by 24
“Five metabolites, namely quercetin, erythronate-4-phosphate, D-glucono-1, 5-lactone, 50,500-diadenosine triphosphate and hydroquinone, were associated with disease complexes, because of experimental binding activity to a member of the complex of Kip1mM, which is a common threshold when considering efficient, small com…”
BackgroundDefining the Cell Surface Cysteinome Using Two-Step Enrichment Proteomics
(2023) · doi:10.1021/jacsau.3c00707 · Cited by 21
D’Oliveira Albanus, R., Finan, G. M., Brase, L., Sweeney, N., Kim, T. Y., Chen, S., Ryoo, Y., Park, J., Guo, Q., Iyer, A. K., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adx0027 · Cited by 19
Mishra, N., Tiwari, V. K., & Schmidt, R. R. (2020) · Carbohydrates in Drug Discovery and Development · doi:10.1016/b978-0-12-816675-8.00001-4 · Cited by 17
Protein–Protein Interaction Prediction for Targeted Protein Degradation
Orasch, O., Weber, N., Müller, M., Amanzadi, A., Gasbarri, C., & Trummer, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137033 · Cited by 17
Su, C.-Y., van der Graaf, A., Zhang, W., Jang, D.-K., Selber-Hnatiw, S., Yang, T.-Y., Butler-Laporte, G., Liang, K. Y. H., Matsuda, F., Costanzo, M. C., et al. (2024) · doi:10.1101/2024.10.17.24315553 · Cited by 17
Role of NR4A family members in myeloid cells and leukemia
Boulet, S., Le Corre, L., Odagiu, L., & Labrecque, N. (2022) · Current Research in Immunology · doi:10.1016/j.crimmu.2022.02.001 · Cited by 17
“They are important in a wide range of physiological processes including development, metabolism or reproduction and their clinical importance is illustrated by the fact that this family of proteins is highly targeted by prescription drugs (Overington et al., 2006).”
Scribble co-operatively binds multiple α1D-adrenergic receptor C-terminal PDZ ligands
Janezic, E. M., Harris, D.-A., Dinh, D., Lee, K.-S., Stewart, A., Hinds, T. R., Hsu, P. L., Zheng, N., & Hague, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-50671-6 · Cited by 15
Lysosomal amino acid transporters as key players in inflammatory diseases
Toyama-Sorimachi, N., & Kobayashi, T. (2021) · International Immunology · doi:10.1093/intimm/dxab069 · Cited by 14
Accurate determination of conformational transitions in oligomeric membrane proteins
Sanz-Hernández, M., Vostrikov, V. V., Veglia, G., & De Simone, A. (2016) · Scientific Reports · doi:10.1038/srep23063 · Cited by 11
Protein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
Cosolvent and Dynamic Effects in Binding Pocket Search by Docking Simulations
(2021) · doi:10.1021/acs.jcim.1c00924 · Cited by 9
Coarse-Graining the Recognition of a Glycolipid by the C-Type Lectin Mincle Receptor
Noriega, M., Corey, R. A., Haanappel, E., Demange, P., Czaplicki, G., Atkinson, R. A., & Chavent, M. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c03242 · Cited by 2
Metadata
- Authors
- Overington, J. P., Al-Lazikani, B., & Hopkins, A. L.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Overington, John P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-12
- Volume
- 5
- Issue
- 12
- Pages
- 993-996
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1968682237
- Cited by
- 3,505
- References
- 29
- Citations by year
- 2026: 82 · 2025: 126 · 2024: 117 · 2023: 127 · 2022: 173 · 2021: 168 · 2020: 190 · 2019: 190 · 2018: 198 · 2017: 215 · 2016: 276 · 2015: 268 · 2014: 245 · 2013: 280 · 2012: 247
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- therapeutic target, molecular targets, protein kinases, polypharmacology, approved drugs
- MeSH terms
- Humans, Technology, Pharmaceutical, Drug Design, Drugs, Investigational, Genome, Human, Drug Delivery Systems, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.